What we do

The Science

Medical Revascularization:

Initial diagnosis of refractory angina by cardiologist
One-time treatment administered by interventional cardiologist during a one-hour angiogram-like procedure on out-patient basis
Uses standard cardiac balloon catheter (wrist or leg access) to deliver CorGene into the three major coronary arteries, and cardiac preconditioning to enhance cell transfection
Therapeutic response in approximately two to four weeks following treatment
CorGene plug and play formulation. Stored at -70ºC and simply thawed at room temperature immediately prior to use
Angiogenic cardiac perfusion improvement in certain patients approximately equivalent to mechanical revascularization (PCI and CABG)

Product Candidate
CorGene
(Angiogenic Gene Therapy)

ANGIOGENIC MECHANISM
OF ACTION

Cardiac SPECT Imaging

CorGene is an investigational gene therapy designed for patients with refractory angina, severe chest pain caused by advanced coronary artery disease that persists despite medications, stents, or bypass surgery.

Delivered through a simple, minimally invasive catheter procedure, CorGene is designed to help the heart grow new blood vessels in areas with reduced blood flow. By activating the body’s natural healing response, the therapy aims to improve circulation to oxygen-starved heart tissue, potentially reducing symptoms and improving quality of life.

The treatment is administered once by an interventional cardiologist during an outpatient procedure that takes approximately one hour. CorGene’s novel approach is intended to restore blood flow where conventional treatment options may no longer provide relief, offering new hope for patients living with refractory angina.